Internal Medicine

A recent landmark study confirms a vital clinical strategy for heart failure (HF) management. Specifically, providing … Do Not Wait: Give the Flu Shot Before Heart Failure DischargeRead more

The POTCAST trial established a significant new strategy for managing patients at high risk for ventricular … A Simple Way to Slash Ventricular Arrhythmia Risk NowRead more

An emulated target trial examined the comparative effectiveness of two major drug classes for type 2 … SGLT-2is vs. GLP-1RAs: Which Drug Lowers Diabetic Foot Risk?Read more

The results of the pivotal DIGIT-HF trial show significant new evidence for a long-used cardiac glycoside. … Major Update: Digitoxin Cuts HFrEF Risk by 18% in Landmark TrialRead more

Relapsed or refractory multiple myeloma (RRMM) is difficult to treat, but true Extramedullary Myeloma (EMM) presents … Breakthrough in High-Risk Myeloma: New Dual-Targeting DataRead more

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a progressive, devastating lysosomal storage … Tividenofusp Alfa: New Hope for Brain-Penetrant MPS II TherapyRead more

Cardiogenic shock involves a severe depression of cardiac function. This critical condition leads to dangerously low … High Mortality in Cardiogenic Shock: New Treatment AvenuesRead more

Drug-resistant, true extramedullary myeloma (EMD) presents a major clinical challenge. This aggressive disease subtype is noncontiguous … Breakthrough: Dual-Targeting Myeloma Agents for EMDRead more

Mucopolysaccharidosis Type II (MPS II), also called Hunter syndrome, is a progressive, rare genetic lysosomal disorder. … Game Changer? New Enzyme Therapy Penetrates Brain in MPS IIRead more

Cardiogenic Shock is a critical syndrome. It occurs when heart function severely declines, leading to low … High Mortality Alert: New Strategies for Cardiogenic ShockRead more